The estimated Net Worth of Enterprise Associates 16, L... is at least $6.38 Million dollars as of 11 April 2022. Enterprise L owns over 2,631,578 units of Metacrine stock worth over $5,157,565 and over the last 6 years Enterprise sold MTCR stock worth over $1,220,183.
Sign up
Enterprise L MTCR stock SEC Form 4 insiders trading
Enterprise has made over 13 trades of the Metacrine stock since 2019, according to the Form 4 filled with the SEC. Most recently Enterprise sold 10,376,936 units of MTCR stock worth $726,386 on 24 May 2022.
The largest trade Enterprise's ever made was selling 10,376,936 units of Metacrine stock on 24 May 2022 worth over $726,386. On average, Enterprise trades about 2,952,616 units every 85 days since 2019. As of 11 April 2022 Enterprise still owns at least 10,421,428 units of Metacrine stock.
You can see the complete history of Enterprise L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Metacrine
Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.
What does Metacrine do?
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
What does Metacrine's logo look like?
Complete history of Enterprise L stock trades at Genocea Biosciences Inc, Mirum Pharmaceuticals Inc, Trevi Therapeutics, Marker Therapeutics, Akouos, and Metacrine
Metacrine executives and stock owners
Metacrine executives and other stock owners filed with the SEC include:
-
Dr. Preston S. Klassen M.D., M.H.S.,
Pres, CEO & Director -
Dr. Preston S. Klassen,
Pres, CEO & Director -
Patricia M. Millican,
Chief Financial Officer -
Catherine C. Lee,
Consultant -
Michael B. York,
Chief Bus. Officer -
Theresa Lowry,
VP of HR -
Patricia Millican,
Chief Financial Officer -
Andrew Guggenhime,
Director -
Jeffrey David Jonker,
Director -
John G Mc Hutchison,
Director -
Venture Fund Viii, L.P.Arch...,
-
Kristina Burow,
Director -
Preston Klassen,
Director -
Enterprise Associates 16, L...,
-
Trisha Millican,
Chief Financial Officer -
Forest Baskett,
10% owner -
Ali Behbahani,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ronald M Evans,
Director -
Carmen Chang,
10% owner -
Mohamad Makhzoumi,
10% owner -
Amir Nashat,
Director -
Management Co. Vii, L.L.C.P...,
-
Joshua Makower,
10% owner -
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Paul Edward Walker,
10% owner -
Global Strategic Fund, L.P....,
-
Robert J Adelman,
-
Hubert C Chen,
Chief Medical Officer -
Catherine Chai Zon Lee,
EVP, Gen. Counsel & Secretary -
Julia C. Owens,
Director -
Richard A. Heyman,
Director -
Global Strategic Fund, L.P....,
-
Michael York,
Chief Business Officer -
Braden Michael Leonard,
10% owner